A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Retinitis Pigmentosa
Interventions
GENETIC

Sub-Retinal Administration of OCU400-301

Sub-Retinal Administration of OCU400-301

Trial Locations (17)

16507

RECRUITING

Erie Retina Research LLC, Erie

33064

RECRUITING

Advanced Research, LLC., Deerfield Beach

33136

RECRUITING

Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami

37232

RECRUITING

Vanderbilt Eye Institute, Nashville

54601

RECRUITING

Gundersen Health System, La Crosse

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

77030

RECRUITING

Baylor College of Medicine, Houston

77401

RECRUITING

Retina Consultants of Texas, Bellaire

78503

RECRUITING

Valley Retina Institute, McAllen

85020

RECRUITING

Associated Retina Consultants, Phoenix

90033

RECRUITING

University of Southern California, Roski Eye Insitute, Los Angeles

92093

RECRUITING

University of Southern Califormia, La Jolla

T2H OC8

RECRUITING

Calgary Retina Consultants, Calgary

T6G 3E1

RECRUITING

University of Alberta, Edmonton

V5Z 3N9

RECRUITING

The University of British Columbia, Vancouver

M4N 3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

H2W 1L4

NOT_YET_RECRUITING

Research Institute of the McGill University Health Centre, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocugen

INDUSTRY